Five-year results of nilotinib 400 mg BID in early chronic phase chronic myeloid leukemia (CML): high rate of deep molecular response--update of the GIMEMA
CML WP Trial CML0307.
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al; Italian Multiple Myeloma Network, GIMEMA
The GIMEMA study continues to affirm the known overall survival benefit of VELCADE-based therapy in patients with previously untreated multiple myeloma.
The GIMEMA study is the first phase 3 study to demonstrate that VELCADE-based maintenance reduces the risk of death by 30 percent in patients with previously untreated multiple myeloma.
Cava M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi p, Baccarani M; GIMEMA
Italian Myeloma Network.
Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA: A report by the GIMEMA
A recent observational database study by GIMEMA
(Gruppo Italiano Malattie EMatologiche dell 'Adulto) also confirmed the utility of the index for predicting time to first treatment (16).
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA
Working Party on Chronic Myeloid Leukemia.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mand elli F, Lo-Coco F, Pelicci PG, Martelli MF; GIMEMA
Acute Leukemia Working Party.